iLab Co.
Latest round
- Series B
Last raised
- Jun 2021
Total raised
- $36M
Investors
- 9
About iLab Co.
, Ltd. is a drug discovery company developing immune response-modulating small-molecule medications to fill gaps in the available therapy alternatives. The company is focusing on creating an oral small-molecule tumor necrosis factor (TNF), which will allow doctors to prescribe low immunogenicity medications to treat rheumatoid arthritis and other related conditions.
Who invested in iLab Co.
9 investors across 2 rounds
See all investors in iLab Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about iLab Co.
Who invested in iLab Co.?
iLab Co. has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has iLab Co. raised?
iLab Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did iLab Co. last raise money?
iLab Co.'s most recent round on record is a Series B, in Jun 2021.
What does iLab Co. do?
iLab Co. is a pharmaceuticals company.
Where is iLab Co. headquartered?
iLab Co. is headquartered in Seongnam-si,, South Korea.
Which VCs invest in companies like iLab Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at iLab Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like iLab Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.